A team of researchers led by Professor Matthias Mann at the Max Planck Institute of Biochemistry in Munich and Professor Ernst Lengyel at the University of Chicago (USA) has taken a major step toward understanding and treating low-grade serous ovarian cancer (LGSC), a form of ovarian cancer that primarily affects younger women and is largely resistant to standard chemotherapy. By combining cutting-edge Deep Visual Proteomics – a breakthrough technology pioneered by the Matthias Mann’s team – with spatial transcriptomics, the researchers uncovered how benign ovarian tumors progress into invasive and metastatic cancer, and identified a promising new treatment strategy.